Cinematic rendering of leiomyosarcoma of the superior mesenteric vein.

Abstract

Investigate the effectiveness of IDegLira, a fixed-ratio combination of insulin degludec/liraglutide, in a real-world setting in patients with type 2 diabetes mellitus in the United Arab Emirates.This non‐interventional study enrolled adults switching to IDegLira from basal insulin (BI) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with/without concomitant oral antidiabetic drugs (OADs). Primary endpoint was change in HbA1c from baseline, assessed using a mixed model for repeated measurements.Among 263 patients (BI ± OADs, n=206; GLP-1 RA ± OADs, n=57), mean baseline HbA1c was 9.29% (78 mmol/mol). After 26 weeks, HbA1c was significantly reduced (BI ± OADs, –0.83% [–9.0 mmol/mol] and GLP-1 RA ± OADs, –1.24% [–13.5 mmol/mol]; both p<0.0001). Fasting plasma glucose (FPG) was significantly reduced (–39.48 mg/dL [BI ± OADs] and –82.49 mg/dL [GLP-1 RA ± OADs]; both p<0.0001). Before treatment initiation, 3/263 patients experienced ≥1 severe hypoglycaemic episode and 7/263 patients experienced ≥1 non-severe hypoglycaemic episode compared with 1/263 patients who had ≥1 severe and 1/263 who had ≥1 non-severe episode at end of study. Body weight decreased significantly among patients switching from BI ± OADs (–1.05 kg [p<0.0001]). Treatment was well tolerated.IDegLira significantly reduced HbA1c and FPG in this real-world setting, along with less frequent episodes of hypoglycaemia. Switching to IDegLira offers effective treatment intensification for type 2 diabetes patients with inadequate glycaemic control.